Similar articles

• Lack of efficacy of inosine pranobex in the treatment of chronic hepatitis C.

  Pardo M, Carreño V. Pardo M, et al. J Hepatol. 1994 Aug;21(2):278. doi: 10.1016/s0168-8278(05)80410-6. J Hepatol. 1994. PMID: 7527438 Clinical Trial. No abstract available.
• Inosine prabonex in the treatment of chronic hepatitis C.

  Laskus T, Radkowski M, Cianciara J. Laskus T, et al. J Hepatol. 1992 Nov;16(3):388. doi: 10.1016/s0168-8278(05)80679-8. J Hepatol. 1992. PMID: 1283173 No abstract available.
• [Isoprinosine therapy in chronic hepatitis C (multicenter placebo-controlled double-blind prospective study)].

  Pár A, Beró T, Brasch G, Gógl A, Kamarás G, Méhesfalvi E, Ozsvár Z, Paál M, Szipöcs I, Telegdy L. Pár A, et al. Orv Hetil. 1993 May 9;134(19):1015-9. Orv Hetil. 1993. PMID: 7684118 Clinical Trial. Hungarian.
• Inosine pranobex in the treatment of HIV infection: a review.

  De Simone C, Famularo G, Tzantzoglou S, Moretti S, Jirillo E. De Simone C, et al. Int J Immunopharmacol. 1991;13 Suppl 1:19-27. doi: 10.1016/0192-0561(91)90120-v. Int J Immunopharmacol. 1991. PMID: 1726683 Review.
• [Immunomodulating treatment of patients with HIV infection].

  Skotnicki AB, Kornaszewski W. Skotnicki AB, et al. Przegl Dermatol. 1989 Jul-Aug;76(4):285-91. Przegl Dermatol. 1989. PMID: 2483589 Review. Polish. No abstract available.